Meloxicam

Meloxicam is a non-steroidal anti-inflammatory agent and has been reported to inhibit the inducible isoform of Cox-2. Studies suggest that Meloxicam is Cox-2 preferential, therefore it will probably not display a lower gastrointestinal toxicity than non-selective anti-inflammatory agents. This compound has been shown to also inhibit prostanoid synthesis in inflammatory cells. It shows potent anti-inflammatory, antipyretic, and analgesic effects with low gastrointestinal toxicity in animal models.

Properties:

Appearance & Physical State: Light Yellow Solid

Density: 1.613 g/cm3

Melting Point: 255ºC

Refractive Index: 1.72

COX Inhibitors Related Products:

Celecoxib; Resveratrol; Indomethacin; Lornoxicam; Amfenac Sodium Monohydrate; S-ketoprofen; Aspirin; Suprofen; Etodolac; Licofelone; ATB-346; FK3311; Deracoxib; Parecoxib; Piroxicam

[1]. Lazer ES, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997 Mar 14;40(6):980-9.

[2]. Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206.

[3]. Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32(2).